| Phase 110 trials |
|
Phase 1
|
NCT07411586 |
Aug 2026 → Jan 2027 expected |
acute myeloid leukemia |
M.D. Anderson Cancer Center |
Not yet recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT07355335 |
Jul 2026 → Jul 2027 expected |
B-lymphoblastic leukemia/lymphoma MLL rearranged, acute myeloid leukemia with mutated NPM1 |
Massachusetts General Hospital |
Not yet recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT06769490 |
Jul 2025 → Sep 2028 expected |
acute myeloid leukemia |
M.D. Anderson Cancer Center |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT06655246 |
Mar 2025 → Dec 2027 expected |
gastrointestinal stromal tumor |
Kura Oncology, Inc. |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT06376162 |
Mar 2025 → Jan 2027 expected |
B-lymphoblastic leukemia/lymphoma MLL rearranged, acute myeloid leukemia with mutated NPM1, acute myeloid leukemia, t(5;11)(q35;p15) |
PedAL BCU, LLC |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT06448013 |
Mar 2025 → Dec 2028 expected |
acute myeloid leukemia |
M.D. Anderson Cancer Center |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT06397027 |
Dec 2024 → Dec 2028 expected |
refractory hematologic cancer |
M.D. Anderson Cancer Center |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT06440135 |
Jun 2024 → Sep 2026 expected |
acute myeloid leukemia with NPM1 somatic mutations, acute myeloid leukemia, MLL gene rearrangement |
Massachusetts General Hospital |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT06001788 |
Feb 2024 → Aug 2026 overdue |
acute myeloid leukemia with mutated NPM1, acute myeloid leukemia, MLL gene rearrangement |
Kura Oncology, Inc. |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT05735184 |
Jul 2023 → Apr 2030 expected |
acute myeloid leukemia with mutated NPM1, acute myeloid leukemia, MLL gene rearrangement, myeloid sarcoma |
Kura Oncology, Inc. |
Recruiting
|
No outcome recorded
|
| Phase 1/22 trials |
|
Phase 1/2
|
NCT05848687 |
Nov 2023 → Dec 2028 expected |
acute lymphoblastic leukemia |
Tanja Andrea Gruber |
Recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT04067336 |
Sep 2019 → Oct 2028 expected |
mixed phenotype acute leukemia with MLL rearranged |
Kura Oncology, Inc. |
Active not recruiting
|
No outcome recorded
|
| Phase 22 trials |
|
Phase 2
|
NCT06930352 |
Sep 2026 → Dec 2027 expected |
acute myeloid leukemia |
Uma Borate |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07623616 |
Apr 2026 → Mar 2027 expected |
acute myeloid leukemia |
Kyowa Kirin, Inc. |
Recruiting
|
No outcome recorded
|
| Phase 31 trial |
|
Phase 3
|
NCT07007312 |
Sep 2025 → Nov 2031 expected |
acute myeloid leukemia |
Kura Oncology, Inc. |
Recruiting
|
No outcome recorded
|
| Phase not stated1 trial |
| — |
NCT05738538 |
— |
B-lymphoblastic leukemia/lymphoma MLL rearranged, acute myeloid leukemia with NPM1 somatic mutations, acute myeloid leukemia, MLL gene rearrangement |
Kura Oncology, Inc. |
Available
|
No outcome recorded
|